« Morning Smoke: After Three-Year Vacancy, Office of Special Counsel Has Permanent Leader | Main | FAPIIS First Impressions »

Apr 18, 2011


Ryan M.

Neither this post nor the editorial it cites appears to be aware of the 2010 trial against Pfizer over Neurontin. In preparation for that trial, Dr. Kay Dickersin of Johns Hopkins did a detailed study of how the ghostwritten literature on Neurontin misrepresented the clinical trial research reports: http://www.nejm.org/doi/full/10.1056/NEJMsa0906126?siteid=nejm&keytype=ref&ijkey=fSALtumKaUpyI
The trial resulted in a $142M RICO verdict against Pfizer, and findings of fact by the judge -- showing that for several off-label indications, Neurontin was no more effective than placebo, despite all of the prescriptions. More on that trial, plus a link to the judge's findings:

The comments to this entry are closed.